dc.contributor.author | Redondo, MJ | |
dc.contributor.author | Morgan, NG | |
dc.date.accessioned | 2023-12-04T14:08:50Z | |
dc.date.issued | 2023-06-19 | |
dc.date.updated | 2023-12-04T09:33:41Z | |
dc.description.abstract | Despite major advances over the past decade, prevention and treatment of type 1 diabetes mellitus (T1DM) remain suboptimal, with large and unexplained variations in individual responses to interventions. The current classification schema for diabetes mellitus does not capture the complexity of this disease or guide clinical management effectively. One of the approaches to achieve the goal of applying precision medicine in diabetes mellitus is to identify endotypes (that is, well-defined subtypes) of the disease each of which has a distinct aetiopathogenesis that might be amenable to specific interventions. Here, we describe epidemiological, clinical, genetic, immunological, histological and metabolic differences within T1DM that, together, suggest heterogeneity in its aetiology and pathogenesis. We then present the emerging endotypes and their impact on T1DM prediction, prevention and treatment. | en_GB |
dc.description.sponsorship | National Institutes of Health (NIH) | en_GB |
dc.description.sponsorship | Diabetes UK | en_GB |
dc.description.sponsorship | Medical Research Council (MRC) | en_GB |
dc.description.sponsorship | JDRF | en_GB |
dc.description.sponsorship | EFSD | en_GB |
dc.description.sponsorship | Innovative Medicines Initiative 2 Joint Undertaking | en_GB |
dc.description.sponsorship | European Union Horizon 2020 | en_GB |
dc.description.sponsorship | EFPIA | en_GB |
dc.description.sponsorship | Leona M. and Harry B. Helmsley Charitable Trust | en_GB |
dc.format.extent | 542-554 | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 19(9), pp. 542-554 | en_GB |
dc.identifier.doi | https://doi.org/10.1038/s41574-023-00853-0 | |
dc.identifier.grantnumber | R01 DK124395 | en_GB |
dc.identifier.grantnumber | R01 DK121843 | en_GB |
dc.identifier.grantnumber | U54 DK118638 | en_GB |
dc.identifier.grantnumber | 115797 | en_GB |
dc.identifier.grantnumber | 945268 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/134724 | |
dc.identifier | ORCID: 0000-0003-1537-8113 (Morgan, Noel G) | |
dc.language.iso | en | en_GB |
dc.publisher | Nature Research | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/37337007 | en_GB |
dc.rights.embargoreason | Under embargo until 19 December 2023 in compliance with publisher policy | en_GB |
dc.rights | © Springer Nature Limited 2023 | en_GB |
dc.title | Heterogeneity and endotypes in type 1 diabetes mellitus | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-12-04T14:08:50Z | |
dc.identifier.issn | 1759-5029 | |
exeter.place-of-publication | England | |
dc.description | This is the author accepted manuscript. The final version is available on open access from Nature Research via the DOI in this record | en_GB |
dc.identifier.eissn | 1759-5037 | |
dc.identifier.journal | Nature Reviews Endocrinology | en_GB |
dc.relation.ispartof | Nat Rev Endocrinol, 19(9) | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
dcterms.dateAccepted | 2023-05-12 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2023-06-19 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-12-04T13:58:47Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2023-12-19T00:00:00Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2023-06-19 | |